"showed potency in" is correct and usable in written English.
You would use this expression when describing something (a person or object) that has been shown to have a great deal of power or influence over a certain situation. For example, "He showed potency in his leadership of the group, quickly implementing successful changes."
Some of the compounds showed potency in cell-based assays and good pharmacokinetic properties.
Trypanocidal activity also showed potency in the low micromolar range and confirms these inhibitors as promising candidates for the development towards the design of anti-trypanosomal drugs.
In this study, NA showed potency in inhibiting the growth of a broad spectrum of tumor cell lines, especially for NPC and breast cancer cells.
RB200 inhibited EGF- and NRG1-β1-stimulated tyrosine phosphorylation of HER1, HER2 and HER3 and also showed potency in cell proliferation assays [ 18].
One technology that has shown potency in generation of antiviral T cell pools in clinical studies is based on replication-deficient adenoviral vectors.
Moreover, RB200 inhibited EGF-stimulated and NRG1-β1-stimulated tyrosine phosphorylation of HER family proteins (HER1, HER2 and HER3) in vitro and has shown potency in a variety of cell proliferation assays [ 18].
Knowledge of the active target sub-space of those drug compounds that show potency in the cell models is fundamental for understanding their mechanism of action, which in turn is critical for the drug development process as well as for drug repurposing applications.
Our results show that out of 78 compounds, three compounds are worth pursuing as leads, as they show potency of ⩾55% in both cancer cell lines.
The potency to rescue the phenotype correlated with the results of the in vitro assay except for compounds 10 and 9 (data not shown), which showed little potency in vitro but were highly active in vivo.
While this compound showed minimal effects in cell viability or gene expression assays, it showed remarkable potency in preventing the emergence of a drug tolerant population in EGFR mutant PC9 cells treated with EGFR inhibitors.
Of these, compound 4 was selected as a starting point for SAR studies, as it showed acceptable potency in the primary assay measuring inhibition of dense granule release (IC50 = 1 10 μM).
